News Novartis AG

Equities

NOVN

CH0012005267

Real-time Estimate Cboe Europe Other stock markets 07:20:25 2024-04-16 am EDT			5-day change	1st Jan Change
84.68 ^CHF	-2.10%		-1.83%	-0.09%

Apr. 12	Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug	MT
Apr. 11	Health Care Slips on Risk Bias -- Health Care Roundup	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Arvinas enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer	Apr. 12	AQ
MorphoSys Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis	Apr. 12	AQ
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug	Apr. 12	MT
Health Care Slips on Risk Bias -- Health Care Roundup	Apr. 11	DJ
Trending : Novartis Begins Tender Offer for MorphoSys Shares	Apr. 11	DJ
Novartis: licensing agreement in prostate cancer	Apr. 11	CF
Novartis: MorphoSys Board recommends tender offer	Apr. 11	CF
MorphoSys Board Supports Norvartis' Buyout Offer as Tender Period Begins	Apr. 11	MT
Morphosys management bodies recommend acceptance of Novartis takeover bid	Apr. 11	DP
Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis	Apr. 11	MT
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact	Apr. 11	DJ
Novartis licenses Arvinas' cancer drug for up to $1 billion	Apr. 11	RE
Arvinas, Inc Enters into an Exclusive Strategic License Agreement with Novartis AG for the Development and Commercialization of Protac Androgen Receptor Protein Degrader Arv-766 for the Treatment of Prostate Cancer	Apr. 11	CI
Novartis begins tender offer for cancer-focused MorphoSys	Apr. 11	RE
NOVARTIS : UBS reiterates its recommendation on the stock	Apr. 11	CF
Novartis Launches Tender Offer for Germany's MorphoSys	Apr. 11	MT
Novartis initiates tender offer for MorphoSys	Apr. 11	CF
Novartis begins tender offer for cancer-focused MorphoSys	Apr. 11	RE
Novartis tender offer for MorphoSys AG commences	Apr. 11	GL
Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2	Apr. 10	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

NOVARTIS : Novartis on course to set new highs

February 20, 2024 at 11:30 am EST

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am EDT